Form 4: IDEXX Laboratories Director Sophie V. Vandebroek Reports Stock Transactions

Director Sophie V. Vandebroek of IDEXX Laboratories reported the disposition of 344 shares and the acquisition of 224 shares of common stock on November 27, 2024.

Summary

• Sophie V. Vandebroek, a director at IDEXX Laboratories, reported transactions involving the company's common stock.
• On November 27, 2024, Ms. Vandebroek acquired 224 shares of common stock through a gift.
• On the same day, she disposed of 344 shares of common stock at a price of $420.435 per share.
• Following these transactions, Ms. Vandebroek directly owns 905 shares of IDEXX Laboratories common stock.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions by a company director, with no indication of positive or negative sentiment.

Industry Context

This is a routine filing related to insider trading activity and is common for directors of publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, such as directors, in accordance with SEC regulations.
• The transactions reported are typical for directors who may receive stock as part of their compensation or may sell shares for personal financial management.
• Similar filings are made by directors and officers of other publicly traded companies like Zoetis (ZTS) and Heska (HSKA) when they trade their company's stock.

Stakeholder Impact

• The reported transactions have a minimal impact on stakeholders as they represent routine trading activity by a company director.

Key Dates

Keywords

IDEXX Laboratories, stock transaction, insider trading, Form 4, Sophie V. Vandebroek, director, share disposal, share acquisition